What the FDA labels say about taking them together
Epinephrine and tranylcypromine
Tranylcypromine's FDA label of July 2, 2025 names epinephrine in its drug interactions section; epinephrine's label does not name tranylcypromine itself but warns about its class (MAO inhibitors). The tranylcypromine label: “Treatment with Contraindicated Drugs If in the absence of therapeutic alternatives emergency treatment with a contraindicated product becomes necessary and cannot be delayed, discontinue PARNATE as soon as possible …”
Check it at the source: the epinephrine FDA label on DailyMed (effective July 13, 2026, A-S Medication Solutions); the tranylcypromine FDA label on DailyMed (effective July 2, 2025, Advanz Pharma (US) Corp.).
What does the epinephrine label say about tranylcypromine?
Epinephrine's label does not name tranylcypromine itself; it warns about its class (MAO inhibitors):
Epinephrine label, drug interactionsDRUG INTERACTIONS Drugs that counter the pressor effects of epinephrine include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. ( 7 .1) Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. …
Epinephrine label, warnings and precautionsPatients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of triptyline or imipramine types may experience severe, prolonged hypertension when given epinephrine.
Source: FDA drug label (Epinephrine), A-S Medication Solutions, effective July 13, 2026 (SPL set 6e811e28-0199-4df7-a916-5940c632401d), via openFDA; the full label on DailyMed
What does the tranylcypromine label say about epinephrine?
Tranylcypromine label, drug interactionsIf in the absence of therapeutic alternatives and emergency treatment with a contraindicated drug (e.g., linezolid, intravenous methylene blue, direct-acting sympathomimetic drugs such as epinephrine) becomes necessary and cannot be delayed, discontinue PARNATE as soon as possible before initiating treatment with the other agent, and monitor closely for adverse reactions.
Tranylcypromine label, warnings and precautionsTreatment with Contraindicated Drugs If in the absence of therapeutic alternatives emergency treatment with a contraindicated product (e.g., linezolid, intravenous methylene blue, direct-acting sympathomimetic drugs such as epinephrine) becomes necessary and cannot be delayed, discontinue PARNATE as soon as possible before initiating treatment with the other product and monitor closely for adverse reactions [see Drug Interactions (7.1)]
Source: FDA drug label (PARNATE), Advanz Pharma (US) Corp., effective July 2, 2025 (SPL set b72d8187-dfcc-4ea0-b5e9-c0be95b69a27), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Epinephrine | Tranylcypromine | |
|---|---|---|
| Labeled for | Asthma | Depression |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $123.51 per unit 0.15 mg auto-injct | $0.591 per tablet 10 mg tablet |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once